BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 31146197)

  • 1. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.
    Sobhy MK; Mowafy S; Lasheen DS; Farag NA; Abouzid KAM
    Bioorg Chem; 2019 Aug; 89():102988. PubMed ID: 31146197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent thieno[2,3-d]pyrimidine VEGFR-2 inhibitors: Design, synthesis and enzyme inhibitory evaluation supported by molecular dynamics simulations.
    Elrazaz EZ; Serya RAT; Ismail NSM; Albohy A; Abou El Ella DA; Abouzid KAM
    Bioorg Chem; 2021 Aug; 113():105019. PubMed ID: 34091286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
    Bhojwani HR; Joshi UJ
    Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
    Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
    Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
    Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
    Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer.
    Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM
    Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
    Sun W; Hu S; Fang S; Yan H
    Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAF
    Wang Y; Wan S; Li Z; Fu Y; Wang G; Zhang J; Wu X
    Eur J Med Chem; 2018 Jul; 155():210-228. PubMed ID: 29886324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
    Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
    Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
    Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M
    Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of novel furan, furo[2,3-d]pyrimidine and furo[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives as potential VEGFR-2 inhibitors.
    Abd El-Mageed MMA; Eissa AAM; Farag AE; Osman EEA
    Bioorg Chem; 2021 Nov; 116():105336. PubMed ID: 34530235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
    Adel M; Serya RAT; Lasheen DS; Abouzid KAM
    Bioorg Chem; 2018 Dec; 81():612-629. PubMed ID: 30248512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives.
    Eldehna WM; Abou-Seri SM; El Kerdawy AM; Ayyad RR; Hamdy AM; Ghabbour HA; Ali MM; Abou El Ella DA
    Eur J Med Chem; 2016 May; 113():50-62. PubMed ID: 26922228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation.
    Abdel-Mohsen HT; Girgis AS; Mahmoud AEE; Ali MM; El Diwani HI
    Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900089. PubMed ID: 31463965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of novel oxazolo[5,4-d]pyrimidines as potent VEGFR-2 inhibitors.
    Deng YH; Xu D; Su YX; Cheng YJ; Yang YL; Wang XY; Zhang J; You QD; Sun LP
    Chem Biodivers; 2015 Apr; 12(4):528-37. PubMed ID: 25879498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles.
    Abdel-Mohsen HT; Abdullaziz MA; Kerdawy AME; Ragab FAF; Flanagan KJ; Mahmoud AEE; Ali MM; Diwani HIE; Senge MO
    Molecules; 2020 Feb; 25(4):. PubMed ID: 32053964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of biphenyl-based VEGFR-2 inhibitors. Part 3: design, synthesis and 3D-QSAR studies.
    Lu W; Li P; Shan Y; Su P; Wang J; Shi Y; Zhang J
    Bioorg Med Chem; 2015 Mar; 23(5):1044-54. PubMed ID: 25637123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors.
    Rajagopalan M; Balasubramanian S; Ramaswamy A; Mathur PP
    J Enzyme Inhib Med Chem; 2013 Dec; 28(6):1236-46. PubMed ID: 23061928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.